ES2065313T1 - Tableta con biodisponibilidad mejorada que contiene acido dicloro metileno difosfonico como sustancia activa. - Google Patents

Tableta con biodisponibilidad mejorada que contiene acido dicloro metileno difosfonico como sustancia activa.

Info

Publication number
ES2065313T1
ES2065313T1 ES93111827T ES93111827T ES2065313T1 ES 2065313 T1 ES2065313 T1 ES 2065313T1 ES 93111827 T ES93111827 T ES 93111827T ES 93111827 T ES93111827 T ES 93111827T ES 2065313 T1 ES2065313 T1 ES 2065313T1
Authority
ES
Spain
Prior art keywords
tablet
active substance
improved bioavailability
acid methylene
methylene diphosphonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES93111827T
Other languages
English (en)
Other versions
ES2065313T3 (es
ES2065313T5 (es
Inventor
Walter Preis
Bernd Musel
Gunter Dr Neugebauer
Rolf-Dieter Dr Gabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25927331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2065313(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE9307393U external-priority patent/DE9307393U1/de
Priority claimed from DE19934322057 external-priority patent/DE4322057A1/de
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of ES2065313T1 publication Critical patent/ES2065313T1/es
Publication of ES2065313T3 publication Critical patent/ES2065313T3/es
Application granted granted Critical
Publication of ES2065313T5 publication Critical patent/ES2065313T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A TABLETAS CON BIODISPONIBILIDAD MEJORADA DE LA SUSTANCIA ACTIVA DICLOROMETILENO ACIDO DIFOSFONICO DE UNA SAL TOLERABLE FISIOLOGICAMENTE Y UN CONTENIDO EN CELULOSA MICROCRISTALINA COMO SUSTANCIA AUXILIAR FARMACEUTICA, EMPAQUETADOS DE ESTE MEDICAMENTO CONTENIENDO ESTAS TABLETAS, LA UTILIZACION DE LA SUSTANCIA ACTIVA DICLOROMETILENO ACIDO DIFOSFONICO CONJUNTAMENTE CON CELULOSA MICROCRISTALINA PARA LA ELABORACION DE UNA TABLETA CON BIODISPONIBILIDAD MEJORADA Y UN PROCEDIMIENTO PARA LA ELABORACION DE LA TABLETA.
ES93111827T 1993-05-15 1993-07-24 Tableta con biodisponibilidad mejorada que contiene acido diclorometilendifosfonico como sustancia activa. Expired - Lifetime ES2065313T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE9307393U DE9307393U1 (de) 1993-05-15 1993-05-15 Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
DE9307393U 1993-05-15
DE4322057 1993-07-02
DE19934322057 DE4322057A1 (de) 1993-07-02 1993-07-02 Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff

Publications (3)

Publication Number Publication Date
ES2065313T1 true ES2065313T1 (es) 1995-02-16
ES2065313T3 ES2065313T3 (es) 1995-12-01
ES2065313T5 ES2065313T5 (es) 2004-01-01

Family

ID=25927331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93111827T Expired - Lifetime ES2065313T5 (es) 1993-05-15 1993-07-24 Tableta con biodisponibilidad mejorada que contiene acido diclorometilendifosfonico como sustancia activa.

Country Status (25)

Country Link
US (1) US5650168A (es)
EP (2) EP0697890A1 (es)
JP (1) JP3699110B2 (es)
KR (1) KR100263284B1 (es)
CN (1) CN1041797C (es)
AT (2) ATE128363T1 (es)
AU (1) AU687744B2 (es)
BR (1) BR9307859A (es)
CA (1) CA2162470C (es)
CZ (1) CZ287984B6 (es)
DE (1) DE59300688D1 (es)
DK (1) DK0625355T5 (es)
ES (1) ES2065313T5 (es)
FI (1) FI111519B (es)
GR (2) GR940300095T1 (es)
HU (1) HU220872B1 (es)
IL (1) IL106743A (es)
NO (1) NO307548B1 (es)
NZ (1) NZ254765A (es)
PL (1) PL173026B1 (es)
RU (1) RU2134103C1 (es)
SK (1) SK281193B6 (es)
TW (1) TW350772B (es)
UA (1) UA39884C2 (es)
WO (1) WO1994026310A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (fi) 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
CZ289261B6 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
US8163306B2 (en) * 2003-09-19 2012-04-24 Sun Pharma Advanced Research Company Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
CN100370972C (zh) * 2006-01-10 2008-02-27 北京申科联华科技有限公司 一种具有益气养阴、活血复脉功效的片剂及制备方法
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (de) * 1977-03-29 1978-10-12 Procter & Gamble Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
DE3804686A1 (de) * 1988-02-15 1989-08-24 Henkel Kgaa Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FI83421C (fi) † 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Also Published As

Publication number Publication date
IL106743A0 (en) 1993-12-08
FI945313A (fi) 1994-12-13
NO307548B1 (no) 2000-04-25
PL173026B1 (pl) 1998-01-30
JPH08509697A (ja) 1996-10-15
HUT70214A (en) 1995-09-28
GR940300095T1 (en) 1995-01-31
GR3017547T3 (en) 1995-12-31
SK4895A3 (en) 1997-01-08
CZ287984B6 (cs) 2001-03-14
JP3699110B2 (ja) 2005-09-28
DK0625355T4 (da) 2003-10-06
AU4702093A (en) 1994-12-12
CA2162470C (en) 1998-06-16
KR100263284B1 (ko) 2000-08-01
FI945313A0 (fi) 1994-11-11
HU9403160D0 (en) 1995-02-28
EP0625355A1 (de) 1994-11-23
KR960702322A (ko) 1996-04-27
IL106743A (en) 1999-11-30
CA2162470A1 (en) 1994-11-24
ES2065313T3 (es) 1995-12-01
CN1041797C (zh) 1999-01-27
HU220872B1 (en) 2002-06-29
NO944405D0 (no) 1994-11-17
AU687744B2 (en) 1998-03-05
PL307133A1 (en) 1995-05-02
RU2134103C1 (ru) 1999-08-10
ES2065313T5 (es) 2004-01-01
EP0697890A1 (de) 1996-02-28
WO1994026310A1 (de) 1994-11-24
CZ10095A3 (en) 1995-10-18
BR9307859A (pt) 1996-01-09
FI111519B (fi) 2003-08-15
NZ254765A (en) 1997-02-24
SK281193B6 (sk) 2001-01-18
NO944405L (no) 1994-11-24
ATE128363T1 (de) 1995-10-15
CN1095267A (zh) 1994-11-23
EP0625355B2 (de) 2003-06-25
UA39884C2 (uk) 2001-07-16
EP0625355B1 (de) 1995-09-27
DK0625355T5 (da) 2003-12-01
US5650168A (en) 1997-07-22
AT128U1 (de) 1995-03-27
DK0625355T3 (da) 1995-12-27
TW350772B (en) 1999-01-21
DE59300688D1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
ES2065313T1 (es) Tableta con biodisponibilidad mejorada que contiene acido dicloro metileno difosfonico como sustancia activa.
TR200000722T2 (tr) Silikatlı küçük kristalli selüloz içeren farmakolojik ilaç.
FI930862A0 (fi) En doseringsform foer tidsvarierande moenster av laekemedeloeverlaotelse
AU1227899A (en) Osmotic medicament releasing system
AR004179A1 (es) Sales de (endo,sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-metil-8-(1- metiletil)-8-azoniabiciclo[3.2.1] octano y preparaciones medicamentosasinhalativas que las contienen.
ES541513A0 (es) Procedimiento para la obtencion de comprimidos de sustancia activa farmaceutica, de rapida desintegracion
DK583789A (da) System til transmucosal indgivelse af den aktive bestanddel af et laegemiddel
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
BR9809268A (pt) Unidade de dosagem farmacêutica, processo para fabricação da mesma, e, uso de um produto de amido como um veìculo para unidades de dosagem farmacêutica compreendendo tibolona
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
ES2103486T3 (es) Medicamentos que contienen acidos difosfonicos y sus sales.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
HUP9903410A2 (hu) Tolfenámsavat vagy gyógyszerészetileg elfogadható sóját tartalmazó, gyors hatóanyag-leadású tabletta
ES532645A0 (es) Una tableta farmaceutica de liberacion controlada
DZ3208A1 (fr) Comprimes faiblement doses et procédé de préparation.
GB1041861A (en) Pyrrolidone derivatives and pharmaceutical preparations containing them
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
PT1001942E (pt) Poli-hidroxibutilpirazinas sua preparacao e medicamentos que as contem
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
BG60697B2 (en) Medicamentous form having continous release based on ethodolacquer
DE9307393U1 (de) Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
GT200000160A (es) Combinacion para el tratamiento de la dependencia de alcohol y las drogas, que contiene un antagonistaopioide y un modular del complejo del receptor de nmda.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625355

Country of ref document: ES